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No official stage classification for thymic malignancieshas been defined by the Union Internationale Contre le
Cancer and the American Joint Commission on Cancer. The
International Thymic Malignancy Interest group (ITMIG) has
selected the Masaoka system1 with the modification proposed
by Koga et al.2 as the one that will be used,3 until a scientifi-
cally validated system is defined in the next edition of the
international tumor staging manuals in 2017. However, there are
details of the Masaoka and Koga classifications that have never
been defined clearly. This article addresses this issue to achieve
consistency in terms from this point forward for ITMIG initia-
tives. We hope that this standard will be adopted by all research-
ers because it will enhance collaboration and definition of a
better classification system in the future.
METHODS
The process used in the development of this document
was designed to represent a broad consensus within the
community of clinicians and researchers interested in thymic
diseases. A core work group drafted proposed definitions
(Frank C. Detterbeck, Cesar Moran, Andrew Nicholson, Ka-
zuya Kondo, and Paul Van Schil), which were refined by an
extended work group (James Huang, Akira Masaoka, Edith
Marom, Nicolas Girard, William Travis, Meinoshin Oku-
mura, and Alexander Brunelli). These were further revised at
an ITMIG Definition and Terminology workshop on Novem-
ber 16, 2010, which was supported by the International
Association for the Study of Lung Cancer. After distribution
to all ITMIG members for comment, the final document was
approved and adopted by ITMIG members in February 2011.
THE MASAOKA-KOGA STAGING SYSTEM
History of Stage Classification
A three-tiered staging system was proposed by Bergh et
al.4 in 1978 (stage I, within the capsule; stage II, extension
into mediastinal fat; and stage III, invasion of surrounding
organs or intrathoracic metastases). A similar system was
proposed 1 year later by Wilkins et al.,5 with the difference
that stage II specifically mentioned extension into the medi-
astinal pleura or pericardium. The four-tiered Masaoka stag-
ing system was proposed in 1981 (based on 93 patients),1 and
a modification of this classification was suggested by Koga et
al.2 in 1994 (based on 79 patients). This modified classifica-
tion system has been used most widely. Many institutions and
authors who state that they use the “Masaoka system” are
actually using the Koga modification when one examines
their definitions. Details regarding these two classification
schemes are discussed in the next section.
Additional stage classification systems have been pro-
posed. Other suggested modifications of the Masaoka system
include subdividing stage I into Ia and Ib groups based on the
presence of absence of adherence without microscopic inva-
sion.6,7 Subdivision of stage III depending on the presence of
great vessel invasion is suggested by Association of Directors
of Anatomic and Surgical Pathology (ADASP).8
Incorporating the completeness of resection into the
classification of stage III and IV was also suggested by some
authors.6,7 A French system proposed in 1991 fully incorpo-
rated the completeness of resection into the classification.9
However, this is really a prognostic classification system,
because it goes beyond anatomic tumor extent (the focus of
stage classification) by including the results of treatment.
Yamakawa et al.10 proposed a tumor, node, metastasis
(TNM) system in 1991 (based on 207 patients), which followed
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the original Masaoka system for the T descriptor and grouped
any N- or M-positive tumor into stage IVb (pleural or pericardial
nodules alone are T4, stage IVa). Modifications of this were
proposed by Tsuchiya et al.11 in 1994 and the World Health
Organization in 2004.12 Bedini et al.13 proposed a modified
TNM system in 2005 (based on a sophisticated analysis of 127
patients), which they call the Istituto Nazionale Tumori system.
They proposed three stage groupings: stage I (locally restricted
disease) essentially includes Masaoka stages I and II with the
exception of mediastinal pleural involvement, stage II (locally
advanced disease) includes tumors invading local structures or
involving intrathoracic lymph nodes, and stage III (systemic
disease) involving cervical nodes or distant extrathoracic sites.
However, none of the TNM systems have been adopted to any
significant degree, and only the Yamakawa system has under-
gone validation studies.14,15
Overview of the System
The Masaoka-Koga classification system is summa-
rized in Table 1. It is focused on the local extension of the
primary tumor, with nodal involvement playing a lesser role.
This is consistent with the observation that nodal involvement
is relatively uncommon with thymomas, although this is not
true for thymic carcinoma.
The original Masaoka system and the Koga modifica-
tion thereof differ in several ways:
Y The Koga system defines stage II as involving transcap-
sular invasion, whereas the Masaoka system refers more
vaguely to capsular invasion.
Y Microscopic invasion into surrounding fat is stage IIa in
the Koga system and IIb in the Masaoka system.
Y The Koga system includes an explicit mention of “ad-
herence to without breaking through the mediastinal
pleura or pericardium.”
There are several nuances that have not been clearly
defined in the Masaoka-Koga system:
Y Exactly what is meant by transcapsular invasion?
Y How should tumors that lack a complete capsule be
defined?
Y How should “macroscopic invasion” be classified that is
shown microscopically not to be present (either of the
perithymic fat or neighboring organs)?
Y Is there a difference between macroscopic invasion and
adherence to the mediastinal pleura or pericardium?
Y What is meant by adherence to the mediastinal pleura or
pericardium?
Y Can we define the difference between “invasion of” and
“breaking through” the mediastinal pleura?
Y The extent of involvement of the pericardium in stage
IIb and stage III is ambiguously worded.
Y How do we know when a separate focus of tumor has
been spread hematogenously?
Y Does the staging system apply to thymic carcinoma as
well?
General criticisms that have been raised about the Ma-
soaka and Masaoka-Koga staging systems are that there is little,
if any, survival difference between stage I and II and that stage
III involves a wide spectrum ranging from transpleural adhe-
sions without invasion to extensive macroscopic and micro-
scopic involvement of the aorta, pulmonary arteries, and heart.
The goal of this article is not to define a new and better staging
system; this will require prospective study and careful analysis.
The goal is to stick to the existing stage classification as closely
as possible but to define nuances, so that prospective data are
recorded in a consistent manner and thereby facilitate a robust
evaluation. However, an awareness of the implications of how
nuances are defined is useful despite the approach of remaining
consistent with the existing classification for the time being.
Stage I
A stage I thymoma is understood to have no transcap-
sular invasion. Invasion into but not through the capsule is
classified as a stage I, localized thymoma (Table 2, Figure 1).
The tumor must breach the capsule to be designated as
invasive (and no longer stage I). Details of the process that
should be used to determine this is addressed in another
article.16
A stage I thymoma is not classified as benign, just as
carcinoma in situ is not considered a benign condition.
Furthermore, all large series with long-term follow-up have
demonstrated recurrences and metastases from stage I thy-
moma of all histologic types.17 Therefore, because all thy-
momas exhibit these hallmarks of malignancy, all thymomas
are considered malignant (although most are low grade and
can be successfully treated).
In some patients, the capsule is partially absent—this
should not be interpreted as invasion. This situation should be
clearly documented in the report (i.e., thymoma, partially unen-
capsulated), and it should be indicated in a note that capsular
invasion cannot be assessed in the areas devoid of a capsule.
However, the tumor should still be designated as stage I unless
there is clear evidence of tumor extension into the mediastinal
fat. It should be recognized that the capsule is not a native
anatomical landmark, rather a reflection of desmoplasia induced
by the tumor, hence, areas that are unencapsulated may exist.
Stage II
A tumor showing transcapsular invasion is designated
as stage II. If there is limited microscopic extension into
tissues surrounding the capsule (i.e., 3 mm), the tumor
TABLE 1. Masaoka-Koga Staging System
Stage Definition
I Grossly and microscopically completely encapsulated tumor
IIa Microscopic transcapsular invasion
b Macroscopic invasion into thymic or surrounding fatty tissue,
or grossly adherent to but not breaking through
mediastinal pleura or pericardium
III Macroscopic invasion into neighboring organ (i.e.,
pericardium, great vessel, or lung)
IVa Pleural or pericardial metastases
b Lymphogenous or hematogenous metastasis
Adapted from Pathol Int 1994;44:359–367.
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should be classified as stage IIa, minimally invasive (Figure 2).16
The tumor should be classified in this manner if extension
beyond the capsule is demonstrated, whether this invades per-
ithymic fat or normal thymus outside of an encapsulated thy-
moma. Conversely, a simple interface of the tumor with the
adjacent tissue in areas devoid of a complete capsule should not
be designated as invasion (should be classified as stage I).
We propose that only microscopically confirmed inva-
sion into adjacent structures be counted; if invasion is sus-
pected but demonstrated microscopically not to be present,
then the initial suspicion should not count in the stage
classification. It should be noted in prospective data collection,
however, so that further clarification of how best to address this
issue can be accomplished. The original Masaoka staging sys-
tem did not require microscopic confirmation of suspected
involvement.1,18 However, the ITMIG consensus is to be con-
sistent with how other malignancies are classified and not
deviate by allowing a gross impression to carry more weight
FIGURE 1. Penetrations within the fibrous capsule of a thy-
moma are classified as noninvasive, although they do (par-
tially) invade the capsule. Absence of a capsule by itself does
not constitute invasion.
FIGURE 2. Schematic diagram of transcapsular invasion
included in stage IIa.
TABLE 2. ITMIG Definition of Details of the Masaoka-Koga
Staging System
Stage Definition (the ITMIG Interpretation of Details Is in Italics)
I Grossly and microscopically completely encapsulated tumor
This includes tumors with invasion into but not through the
capsule, or 
Tumors in which the capsule is missing but without invasion
into surrounding tissues
IIa Microscopic transcapsular invasion
Microscopic transcapsular invasion (not grossly appreciated)
b Macroscopic invasion into thymic or surrounding fatty tissue,
or grossly adherent to but not breaking through
mediastinal pleura or pericardium
Gross visual tumor extension into normal thymus or
perithymic fat surrounding the thymoma
(microscopically confirmed), or 
Adherence to pleura or pericardium making removal of these
structures necessary during resection, with microscopic
confirmation of perithymic invasion (but without
microscopic extension into or through the mediastinal
pleura or into the fibrous layer of the pericardium)
III Macroscopic invasion into neighboring organ (i.e., pericardium,
great vessel, or lung)
This includes extension of the primary tumor to any of the
following tissues:
Microscopic involvement of mediastinal pleura (either
partial or penetrating the elastin layer); or 
Microscopic involvement of the pericardium (either partial
in the fibrous layer or penetrating through to the
serosal layer); or 
Microscopically confirmed direct penetration into the outer
elastin layer of the visceral pleura or into the lung
parenchyma; or 
Invasion into the phrenic or vagus nerves (microscopically
confirmed, adherence alone is not sufficient); or 
Invasion into or penetration through major vascular
structures (microscopically confirmed);
Adherence (i.e., fibrous attachment) of lung or adjacent
organs only if there is mediastinal pleural or
pericardial invasion (microscopically confirmed)
IVa Pleural or pericardial metastases
Microscopically confirmed nodules, separate from the
primary tumor, involving the visceral or parietal pleural
surfaces, or the pericardial or epicardial surfaces,
b Lymphogenous or hematogenous metastasis
Any nodal involvement (e.g., anterior mediastinal,
intrathoracic, low or anterior cervical nodes, any other
extrathoracic nodes)
Distant metastases (i.e., extrathoracic and outside the
cervical perithymic region) or pulmonary parenchymal
nodules (not a pleural implant)
ITMIG, International Thymic Malignancy Interest group.
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than what is seen microscopically. Furthermore, it creates a
more logical progression in the Masaoka-Koga system, with
stage IIa being minimally invasive (microscopically confirmed)
and IIb grossly invasive (microscopically confirmed).
Masaoka-Koga stage IIb tumors are grossly invasive
into surrounding thymic or mediastinal fatty tissue (which is
microscopically confirmed, Figure 3A,B). We propose that
this should include tumors with extension up to the mediastinal
pleura or pericardium without involvement thereof. We recog-
nize that this may be difficult to distinguish.Whenever the tumor
extends close to the mediastinal pleura or pericardium without
invasion, the distance from the tumor to the pleura or pericar-
dium should be noted. Details of the process that should be used
to assess this is addressed in another article.16
FIGURE 3. A and B, Types of invasion included in stage IIb. This may range from (A) a single area of localized invasion to (B)
more extensive involvement of the mediastinal fat without pleural or pericardial involvement.
FIGURE 4. A and B, Types of invasion included in stage III. A, Schematic diagram of involvement of the mediastinal pleura or
partial involvement of the pericardium, or vessels. B, Penetration through the pericardium, the visceral pleura, or into the
phrenic nerve.
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The decision to draw the line differentiating stage IIb
and III at the level of any involvement of the mediastinal
pleura or pericardium is primarily because this seems to be
most consistent with the existing Masaoka-Koga classifica-
tion (stage III: “macroscopic invasion into …pericardium”).
Furthermore, no invasion is probably just as easy (or difficult)
to define as partial invasion or penetration of mediastinal
pleura or pericardium. Finally, in the past, the mere identifi-
cation of the mediastinal pleura in particular has been incon-
sistent, and any attempt to pay attention more consistently to
this structure represents a step forward.16 Prospective study of
this issue is needed to arrive at a delineation of stages that is
less arbitrary and is supported by data.
If there is suspicion of tumor involvement grossly into
the mediastinal pleura or pericardium, but microscopically
this is not the case, the tumor should be noted as adherent, but
classified as stage I, IIa, or IIb as indicated by the microscopic
findings. This should be described as “tumor adherent to but
not invading” the mediastinal pleura or pericardium in the
pathology report. A clear definition of adherence is difficult
to articulate; we propose this should mean that the tumor
appears to be grossly so close to the pleura or pericardium
that resection is deemed necessary. Distinguishing between
simple adherence without invasion and microscopic invasion
of the mediastinal pleura or pericardium represents a devia-
tion from how the Masaoka or Koga classification systems
seem to have been originally defined.1,18 Nevertheless, con-
sistency with the classification of other malignancies de-
mands this interpretation, and therefore, this represents the
consensus of the ITMIG members. Prospective evaluation of
this issue is needed.
Stage III
The pericardium is mentioned somewhat ambiguously
in the Masaoka-Koga classification in both stage IIb and III.
We propose that any involvement (either partial or penetrat-
ing) of the mediastinal pleura or pericardium should be
classified as stage III, and that prospective data be collected
on these nuances. A note should be made in the pathology
report if there is invasion only into the fibrous layer of the
pericardium or if there is penetration into the serosal layer or
onto the serosal pericardial surface. The mediastinal pleura is
a much less substantial structure. We propose that a discon-
tinuous elastin layer with adjacent tumor be classified as
evidence of mediastinal pleural involvement (Figure 4A,B).
Tumor invading across the pleural space to involve the
visceral pleura is also designated as stage III. The pathology
report should note if the visceral pleura is disrupted (using
elastin stains if necessary). Tumor invasion into the lung
parenchyma or invasion into the innominate vein or other
vascular structures warrants a stage III designation (either
partial invasion or penetration, microscopically confirmed).
We propose that tumor invasion into the phrenic or vagus
nerves should be counted as stage III, although this is not
specified in the Masaoka-Koga classification. Which organs
are involved and the extent of involvement (invasion into or
through) should be recorded for future study.
Stage III should be assigned according to the principle
that microscopic findings are the final determinant rather than
a gross impression that is not borne out microscopically.
Therefore, adherence alone of such structures as the lung,
phrenic nerve, or pericardium should not count if lack of
involvement is demonstrated microscopically. Microscopic
invasion into the mediastinal pleura, pericardium, phrenic
nerve, etc. is required to classify the tumor as stage III, even
if there are adhesions of these structures to the tumor of
thymus. Only direct invasion of the primary tumor should be
counted with respect to intrapericardial structures; involve-
ment of the exterior surface of the aorta, superior vena cava,
FIGURE 5. A and B, Separate foci of tumor included in stage IV. A, Separate nodule on the pleural or pericardial surfaces
classified as IVa. B, Involvement of nodal sites, extrathoracic sites, or parenchymal lung nodules.
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or pulmonary artery by a separate and distinct tumor implant
should be classified as stage IVa.
Stage IVa
Pleural or pericardial tumor nodules that are separate
from the primary tumor are classified as stage IVa. These
separate tumor nodules may be located on the visceral or
parietal pleural or the pericardial or epicardial surfaces (Fig-
ure 5A). Direct extension of a thymic malignancy to the
pericardial or pleural surface without separate nodules is
classified as stage III.
Stage IVb
Involvement of nodes close to the thymus is stage IVb.
This includes nodes in the anterior mediastinum, the paratra-
cheal, and subcarinal regions and nodes along the superior
poles of the thymus gland. Nodes elsewhere in the mediasti-
num or within the chest should also be included in this stage
classification as well. Extrathoracic nodes (with the exception
of neck nodes next to the thymus) should be thought of as
distant metastases (but would not change the stage classifi-
cation); this is consistent with the definition used for other
tumors (e.g., lung cancer).
Pulmonary nodules that are in the lung, with a rim of
normal lung between the nodule and the pleural surface are
regarded as distant metastases. Involvement of extrathoracic
tissues (excluding the cervical perithymic areas) should be
classified as distant metastases (Figure 5B).
We propose using the terms pulmonary and extratho-
racic metastases rather than hematogenous metastases. The
former term describes an anatomic location which is factual,
whereas the latter implies a mechanism of spread that is
purely speculative. There are no data to prove the presumed
mechanisms, and an increasing body of data from other
tumors suggests that the process of metastatic spread is
complex, involving factors related to adhesion, migration,
implantation, angiogenesis, etc. and not simply the presence
of tumor cells in the bloodstream.
DISCUSSION
Many of the definitions proposed in this document are
arbitrary, and we accept that alternative definitions may be
equally or more valid. Prospective study is needed to resolve
these issues. This calls for a database with sufficient detail to
study these nuances. It also requires consistent data, which
mandates consensus around a starting point. The definitions
proposed here represent exactly such a consensus; they are
inherently somewhat arbitrary and largely not validated and
are subject to change in the future once sufficient data are
available.
The proposed definitions have focused primarily on
pathologic staging, because that is the focus of the Masaoka-
Koga system. We recognize the need for better definition of
preoperative clinical stage characteristics, but this article only
addresses the need for consistent interpretation of an existing
stage classification system. Definition of clinical staging
characteristics must be addressed separately.
The definitions adopted by ITMIG in this document
arguably represent some minor deviations from the previ-
ously published Masaoka-Koga system. The previous publi-
cations did not define precisely what constituted mediastinal
pleural or pericardial involvement, and one can argue where
the dividing line should be drawn. In fact, such a debate has
occurred during the process of creation of this document, and
the proposed definitions represent the final consensus on what
was felt to be a reasonable (but arbitrary) consistent starting
point. Perhaps, the most clear deviation from the previously
published wording of the Masaoka and Koga stage classifi-
cations is the requirement that macroscopic suspicion of
involvement be confirmed microscopically (for pathologic
stage). This position is taken in virtually every other tumor
type, and it seems wise not to adhere to a different standard
for thymic malignancies.
ITMIG proposes that the Masaoka-Koga stage classifi-
cation be applied to thymoma and thymic carcinoma (includ-
ing thymic carcinoid tumors and other less common types of
thymic malignancy). In the absence of data, it seems better to
maintain consistency and simplicity. Because nodal involve-
ment is much more common in thymic carcinoma than
thymoma, this may prove to be problematic. However, add-
ing significant complexity by having two different definitions
should be based on compelling data that this is worthwhile.
CONCLUSION
ITMIG has chosen to use the Masaoka-Koga stage
classification system, consistent with what has been adopted
most broadly. Nevertheless, many nuances have never been
clearly defined and are often interpreted differently. These
nuances are defined in this document to achieve more con-
sistent application of the Masaoka-Koga stage classification
system. These definitions will be used in ITMIG projects and
studies, and we hope that these will be voluntarily adopted
worldwide, so that collaboration is facilitated. At the same
time, prospective data collection will allow future evaluation
of the appropriateness of the definitions as proposed in this
document.
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